{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Rios AV"],"funding":["Mayo Foundation for Medical Education and Research","Hyundai Hope On Wheels","NIAID NIH HHS","King&amp;apos;s College London","University of Minnesota","Mayo Clinic","NCI NIH HHS","National Institutes of Health","Richard M. Schulze Family Foundation"],"pagination":["5489-5504"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12502006"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["33(11)"],"pubmed_abstract":["Immune tolerance restricts the number of T cells with significant affinity for self-tumor-associated antigens (TAAs), thereby limiting successful cancer immunotherapy through an inability to generate populations of high-affinity anti-tumor T cells. In contrast, viral infection/vaccination primes and expands high-affinity effector and memory T cells against viral antigens. We show here that it is possible to exploit population-wide preexisting, anti-viral memory recall responses against SARS-CoV-2 antigens to focus a high-affinity, immunodominant T cell response into tumors by oncolytic virus (OV)-mediated or chimeric antigen receptor (CAR)-mediated delivery of viral antigens that are not themselves related to TAAs. Heterologous prime and OV/boost led to CD8<sup>+</sup> T cell-dependent tum"],"journal":["Molecular therapy : the journal of the American Society of Gene Therapy"],"pubmed_title":["Exploiting viral infection/vaccination to focus high-affinity T cell populations into tumors using oncolytic viro-immunotherapy."],"pmcid":["PMC12502006"],"funding_grant_id":["R01 AI170535","P50 CA210964","R01 CA269384","CA210964-06A1 P3"],"pubmed_authors":["Tonne J","Metko M","Vile R","Rios AV","Thompson J","Barry MA","Kendall B","Mudrick H","Chen A","Irshad S","Barry M","Diaz RM","Masopust D"],"additional_accession":[]},"is_claimable":false,"name":"Exploiting viral infection/vaccination to focus high-affinity T cell populations into tumors using oncolytic viro-immunotherapy.","description":"Immune tolerance restricts the number of T cells with significant affinity for self-tumor-associated antigens (TAAs), thereby limiting successful cancer immunotherapy through an inability to generate populations of high-affinity anti-tumor T cells. In contrast, viral infection/vaccination primes and expands high-affinity effector and memory T cells against viral antigens. We show here that it is possible to exploit population-wide preexisting, anti-viral memory recall responses against SARS-CoV-2 antigens to focus a high-affinity, immunodominant T cell response into tumors by oncolytic virus (OV)-mediated or chimeric antigen receptor (CAR)-mediated delivery of viral antigens that are not themselves related to TAAs. Heterologous prime and OV/boost led to CD8<sup>+</sup> T cell-dependent tum","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-06-16T03:09:48.326Z","creation":"2026-06-16T03:06:43.91Z"},"accession":"S-EPMC12502006","cross_references":{"pubmed":["40842156"],"doi":["10.1016/j.ymthe.2025.08.023"]}}